Systemic vasculitis: how little we know about their societal and economic burden by L. Trieste et al.
S-154
1Istituto di Management, Scuola Superiore 
Sant’Anna, Pisa, Italy; 
2Rheumatology Unit, Department of  
Internal Medicine, University of Pisa, 
Italy;
3Fondazione Charta, Milan, Italy. 
Leopoldo Trieste, PhD
Ilaria Palla
Chiara Baldini, MD, PhD
Rosaria Talarico, MD, PhD
Lucia D’Angiolella
Marta Mosca, MD, PhD
Giuseppe Turchetti, PhD, Fulbright Scholar
Please address correspondence to: 
Prof. Giuseppe Turchetti, 
Istituto di Management, 
Scuola Superiore Sant’Anna, 
Piazza Martiri della Libertà 33, 
56127 Pisa, Italy.
E-mail: g.turchetti@sssup.it
Received and accepted on October 1, 
2012.
Clin Exp Rheumatol 2012; 30 (Suppl. 73): 
S154-S156.
© Copyright CLINICAL AND 
EXPERIMENTAL RHEUMATOLOGY 2012.
Key words: systemic vasculitis, 
direct costs, indirect costs. 
Competing interests: none declared.
ABSTRACT 
This article attempts to perform an 
evaluation of the state of the art of the 
economic and societal burden of sys-
temic vasculitis (VAs). Due to the rar-
ity of these diseases and their variable 
clinical picture, few data are available 
in the literature on their health eco-
nomic issues, and only some papers 
have been published that marginally 
examine the problem. 
Since VAs are severe conditions with a 
high medical and societal impact and 
determine high healthcare resource con-
sumption, studies able to deﬁne societal, 
quality of life and economic burden of 
these pathologies are needed. Policy 
makers, private and public organisa-
tions involved in the care of VAs need 
data to programme future investment or 
make cost-effectiveness analysis for in-
troducing new drugs or protocols. 
Introduction
Systemic vasculitis (VAs) are an het-
erogeneous group of diseases, often 
characterised by a severe course. It may 
therefore be argued that, in addition 
to the impact on patients outcome and 
prognosis, these conditions, as many 
other rheumatic diseases, may have a 
high impact on the healthcare systems, 
the health care costs, and the society 
(1-3).
Aim of the present review is to exam-
ine the last decade literature studies on 
the issue of healthcare costs in VAs.
The review agrees the recommenda-
tions of the Centre for Reviews and 
Dissemination (4) and of the Cochrane 
Collaboration (5), thereby using an 
established rigorous and reproducible 
methodology. A protocol was devel-
oped to deﬁne review questions.
Methods
Published studies in English were 
searched using the main electronic 
database, PubMed MEDLINE. The 
search was performed for the period 
January 2002–September 19, 2012. The 
search strategy is as follows: ((“econom
ics”[Subheading] OR “economics”[All 
Fields] OR “cost”[All Fields] OR “costs 
and cost analysis”[MeSH Terms] OR 
(“costs”[All Fields] AND “cost”[All 
Fields] AND “analysis”[All Fields]) OR 
“costs and cost analysis”[All Fields]) 
AND (“vasculitis”[MeSH Terms] 
OR “vasculitis”[All Fields])) AND 
((“2002/01/01”[PDAT]: “2012/09/19” 
[PDAT]) AND “humans” [MeSH 
Terms] AND English[lang] AND 
“adult”[MeSH Terms]).
The publications were assessed for in-
clusion by a 3-step process: i. titles and 
abstracts of all identiﬁed studies were 
assessed by one reviewer and checked 
by a second reviewer; ii. full texts of 
relevant articles were then obtained and 
inclusion criteria applied independently 
by two reviewers. Possible discords be-
tween reviewers were resolved by con-
sensus; iii. data were extracted by one 
reviewer and then checked by a second 
reviewer.
Inclusion criteria
In the study protocol the reviewers se-
lected publications from the mentioned 
database as follows:
Period: Jan. 2002–Sep. 19, 2012
Language: English
Studies: all articles related to economic 
analysis
Patients: adult ≥18 
Outcomes: direct costs, indirect costs
Exclusion criteria
Not published in English and all pub-
lications before 2002, conferences 
proceedings, case reports, reviews, 
systematic reviews, letters and com-
mentaries were excluded. 
Results
Up to September 19 2012, 35 articles 
were extracted, but only 3 papers were 
considered relevant to this review 
(Fig. 1) (6-8). 
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Excluded articles had no indications 
of societal and/or economic impacts 
or considered only the impact of some 
therapies. Based on these results, a sys-
tematic literature review was not possi-
ble and therefore data are summarised 
below as a descriptive review.
The societal and economic impact 
of VAs  
Single studies have examined the soci-
etal impact of VAs. Reinhold-Keller et 
al. (8) registered a very high frequency 
of hospitalisation and visits for Wege-
ner’s granulomatosis (WG) patients. 
More than the half of WG patients had 
been hospitalised in the year before the 
study. In extreme cases these authors 
registered one visit a week. 
As far as the employment status was 
concerned, 27% of patients were un-
employed because of the disease, while 
employed patients reported a mean of 
14 workdays lost per year because of 
WG. 
In this study, having WG diagnosis and 
being unemployed was associated with 
reduction of social and physical func-
tioning.
Few studies speciﬁcally addressing 
costs in VAs are available. Krulichova 
et al. (6) estimate the amount of re-
sources used and direct medical costs 
associated to active versus inactive 
Takayasu’s arteritis (TA) in Italy, in a 
multicentre and prospective study. 
The study reports €5054.3 vs. €1328.4 
of mean annual costs per TA active 
and TA inactive patients, respectively. 
These costs are mainly generated by 
drug therapy (22.0% of the total costs) 
and hospitalisation (44.8% of total 
costs), measured using Diagnosis Re-
lated Groups (DRGs). 
The direct and indirect costs associated 
to Behçet’s syndrome (BS) are  report-
ed by Sut et al. (7). The study includes 
119 Turkish BS patients  divided into 
four groups based on the presence of 
ocular, vascular, neurological and mu-
cocutaneous-joint involvement. 
Direct annual per patient costs ($2203 
on average) fall in a interval with a left-
bound of $973 for mucocutaneous-joint 
patients’ subgroup and a right-bound 
of $2727 for the ocular patients’ sub-
group. 
Indirect annual per patient costs are 
$1023, on average. Highest costs have 
been registered within the neurological 
subgroup ($2190) and the lowest cost 
within the mucocutaneous-joint pa-
tients’ subgroup. 
As a result, the study reports $3226 of 
total annual per patient BS related costs 
with $5005 for the neurological sub-
group, $1280, $679 and $207 within the 
ocular, vascular and mucocutaneous-
joint subgroups, respectively.  These 
results should be treated with caution 
because of the very high standard de-
viations reported. 
Discussion and conclusions 
The paucity of studies on direct and in-
direct costs of VAs made a systematic 
review not possible.
The few studies assessing direct costs 
suggest that VAs determine high costs 
related with their severity, the need for 
frequent hospitalisation and costly pro-
cedures. 
Contrarily to other rheumatic diseases 
as far as indirect costs are concerned, 
although many data are available in the 
literature on outcomes and quality of 
life in these conditions (8-16), no de-
tailed analysis are available on the con-
sequences of a poor quality of life on 
employment, salaries and productivity.
The lack of a consolidated literature on 
this theme is a good opportunity to de-
sign and conduct ad hoc studies – also 
deﬁning the criteria and the issues that 
must be included in the analysis – in 
order to obtain statistically signiﬁcant 
and cross countries comparable results 
useful also for deriving health policy 
implications (17, 18). 
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